Logo image of RHO.DE

ROCHE HOLDING AG-BR (RHO.DE) Stock Price, Quote, News and Overview

FRA:RHO - Deutsche Boerse Ag - CH0012032113 - Common Stock - Currency: EUR

306  +0.4 (+0.13%)

RHO.DE Quote, Performance and Key Statistics

ROCHE HOLDING AG-BR

FRA:RHO (6/6/2025, 7:00:00 PM)

306

+0.4 (+0.13%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap247.63B
Shares809.25M
Float688.71M
Yearly Dividend10.76
Dividend Yield3.62%
PE15.27
Fwd PE13.79
Earnings (Next)07-24 2025-07-24
IPO05-04 2001-05-04


RHO.DE short term performance overview.The bars show the price performance of RHO.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0.5 1 1.5 2 2.5

RHO.DE long term performance overview.The bars show the price performance of RHO.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of RHO.DE is 306 EUR. In the past month the price increased by 1.12%.

ROCHE HOLDING AG-BR / RHO Daily stock chart

RHO.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1LLY.MI ELI LILLY & CO 55.96 639.63B
LLY.DE ELI LILLY & CO 55.92 639.16B
ZEG.DE ASTRAZENECA PLC 16.7 396.70B
1JNJ.MI JOHNSON & JOHNSON 15.44 327.23B
JNJ.DE JOHNSON & JOHNSON 15.42 326.84B
NOV.DE NOVO NORDISK A/S-B 20.81 291.26B
SNW.DE SANOFI 11.5 215.21B
SAN.PA SANOFI 11.5 215.16B
NOT.DE NOVARTIS AG-REG 14.26 204.46B
1NOVN.MI NOVARTIS AG-REG 13.64 195.53B
6MK.DE MERCK & CO. INC. 10.18 174.52B
1MRKX.MI MERCK & CO. INC. 10.01 171.75B

About RHO.DE

Company Profile

RHO logo image Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Company Info

ROCHE HOLDING AG-BR

Grenzacherstrasse 124

Basel BASEL-STADT CH

Employees: 103249

RHO Company Website

RHO Investor Relations

ROCHE HOLDING AG-BR / RHO.DE FAQ

What is the stock price of ROCHE HOLDING AG-BR today?

The current stock price of RHO.DE is 306 EUR. The price increased by 0.13% in the last trading session.


What is the ticker symbol for ROCHE HOLDING AG-BR stock?

The exchange symbol of ROCHE HOLDING AG-BR is RHO and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is RHO.DE stock listed?

RHO.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for ROCHE HOLDING AG-BR stock?

27 analysts have analysed RHO.DE and the average price target is 340.35 EUR. This implies a price increase of 11.22% is expected in the next year compared to the current price of 306. Check the ROCHE HOLDING AG-BR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ROCHE HOLDING AG-BR worth?

ROCHE HOLDING AG-BR (RHO.DE) has a market capitalization of 247.63B EUR. This makes RHO.DE a Mega Cap stock.


How many employees does ROCHE HOLDING AG-BR have?

ROCHE HOLDING AG-BR (RHO.DE) currently has 103249 employees.


What are the support and resistance levels for ROCHE HOLDING AG-BR (RHO.DE) stock?

ROCHE HOLDING AG-BR (RHO.DE) has a resistance level at 306.01. Check the full technical report for a detailed analysis of RHO.DE support and resistance levels.


Is ROCHE HOLDING AG-BR (RHO.DE) expected to grow?

The Revenue of ROCHE HOLDING AG-BR (RHO.DE) is expected to grow by 4.26% in the next year. Check the estimates tab for more information on the RHO.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ROCHE HOLDING AG-BR (RHO.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ROCHE HOLDING AG-BR (RHO.DE) stock pay dividends?

ROCHE HOLDING AG-BR (RHO.DE) has a dividend yield of 3.62%. The yearly dividend amount is currently 10.76. Check the full fundamental report for a detailed analysis of RHO.DE dividend history, reliability and sustainability.


When does ROCHE HOLDING AG-BR (RHO.DE) report earnings?

ROCHE HOLDING AG-BR (RHO.DE) will report earnings on 2025-07-24.


What is the Price/Earnings (PE) ratio of ROCHE HOLDING AG-BR (RHO.DE)?

The PE ratio for ROCHE HOLDING AG-BR (RHO.DE) is 15.27. This is based on the reported non-GAAP earnings per share of 20.04 and the current share price of 306 EUR. Check the full fundamental report for a full analysis of the valuation metrics for RHO.DE.


RHO.DE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to RHO.DE.


Chartmill TA Rating
Chartmill Setup Rating

RHO.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to RHO.DE. RHO.DE gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RHO.DE Financial Highlights

Over the last trailing twelve months RHO.DE reported a non-GAAP Earnings per Share(EPS) of 20.04. The EPS increased by 1.24% compared to the year before.


Industry RankSector Rank
PM (TTM) 13.68%
ROA 8.13%
ROE 26.06%
Debt/Equity 0.98
Chartmill High Growth Momentum
EPS Q2Q%1.18%
Sales Q2Q%5.91%
EPS 1Y (TTM)1.24%
Revenue 1Y (TTM)3.03%

RHO.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 70% to RHO.DE. The Buy consensus is the average rating of analysts ratings from 27 analysts.

For the next year, analysts expect an EPS growth of 10.74% and a revenue growth 4.26% for RHO.DE


Ownership
Inst Owners39.03%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts69.63
Price Target340.35 (11.23%)
EPS Next Y10.74%
Revenue Next Year4.26%